Drug Targeting is a collation of methods to actively increase concentration of drug to cells and tissues of interest. Drug targeting can be achieved using various approaches, such as drug formulations or conjugating the active drug to a targeting ligand. These approaches can improve the therapeutic window for drugs by decreasing drug exposure to nontarget tissues, reduce the therapeutic dose and can expand the drugable target space. Targeted delivery can be used for different types of drug modalities (e.g. small molecule, peptides, nucleotide therapeutics). Although, these methods have shown promising effects in pre-clinical and clinical trials they also come with experimental, bioanalytical, data analytical and regulatory challenges to actually demonstrate, study and document efficient and safe drug targeting. The focus on 14th Symposium is to address the pharmacokinetic, bioanalytical, pharmacodynamics, safety and regulatory aspect of active drug targeting.
Who should attend?
This multidisciplinary conference will be of interest to anyone engaged in drug discovery and development. Expected participants include academic and industrial scientists as well as regulatory assessors, working on DMPK, toxicology, pharmacodynamics and pharmaceutics. We also encourage students to attend through a favorable student fee.
The conference aims to cover the following areas:
- General understanding of targeted delivery and different strategies for targeted drug delivery
- Experimental and Measurement techniques for assessing drug targeting
- Drug metabolism and targeted drug delivery
- Pharmacokinetic/Pharmacodynamic considerations for drug targeting
- Safety and regulatory aspects for targeted drug delivery
Confirmed speakers
Prof. Johan Gabrielsson, Swedish University of Agricultural Sciences, Uppsala, Sweden – Candle light speaker; Steve Hood, GSK, UK; Enrico Mastrobattista, Dept. of Agriculture, University of Borås. Pharmaceutics, Utrecht University, The Netherlands ; Dario Neri, Swiss Federal Institute of Technology (ETH Zurich), Switzerland ; Margareta Hammarlund-Udenaes, Uppsala University, Sweden; Shalini Andersson, AstraZeneca, Sweden; Elin Lindhagen, Medical Product Agency, Uppsala Sweden; Carina Ämmälä, AstraZeneca, Sweden; Michael Kurczy, AstraZeneca, Sweden; Camilla Svensson, Medical Products Agency, Uppsala, Sweden
**The symposium will take place at Scandic hotel Rubinen in Gothenburg on March 29 and at AstraZeneca Gothenburg on March 30.
